Header
Ihr Suchergebnis
Sie recherchieren derzeit unangemeldet.Melden Sie sich an (Login) um den vollen Funktionsumfang der Datenbank nutzen zu können.
Sie suchen in allen Bereichen nach dem Autor Rehm A.
In der Rubrik Zeitschriften haben wir 2 Beiträge für Sie gefunden
-
MerkenSupply Chain Management
Rubrik: Fachthemen
(Treffer aus pharmind, Nr. 09, Seite 1222 (2018))
Müßig R | Frey F | Rehm A | Malbrant S
Supply Chain Management / Part 5: Creating Supply Chain Flexibility through Postponement*Part 1 see Pharm Ind. 2015;77(10):1452–1457; Part 2 see Pharm Ind. 2016;78(9):1270–1275; Part 3 see Pharm Ind. 2016;78(11):1580–1587 and Part 4 see Pharm Ind. 2018;80(7):916–923. · Müßig R1, Frey F2, Rehm A2, Malbrant S1 · 1Camelot Management Consultants AG, Mannheim und 2Schreiner, Oberschleißheim und MediPharm
Flexibilität in der Supply Chain mit Postponement-Strategien
-
Dr. Axel Sinner
MerkenSupply Chain Management
Rubrik: Fachthemen
(Treffer aus pharmind, Nr. 11, Seite 1580 (2016))
Supply Chain Management / Part 3: Creating Value – For and Around the Patient * Part 1 see Pharm Ind. 2015;77(10):1452–1457; Part 2 see Pharm Ind. 2016;78(9):1270–1275. · Sinner A, Braun U, Rehm A · 1Camelot Management Consultants AG, Mannheim und 2Schreiner MediPharm, Oberschleißheim
Some years ago, the pharmaceutical industry was shocked by changing market conditions, such as the German AMNOG influence in the overall European market and increased demand for proof of real-world evidence of the treatment with new medications in the US. At the same time, many pharmaceutical companies were facing patent cliffs. In fact, the overall business model of innovative pharma was questioned for a while. A changed mindset led to the introduction of new products which have either provided additional benefits or are expected to show such benefits in the real world. As more pharma companies realize improved outcomes with ...
